168 related articles for article (PubMed ID: 28194654)
1. The Risk of Ischemic Cardio- and Cerebrovascular Events Associated with Oxycodone-Naloxone and Other Extended-Release High-Potency Opioids: A Nested Case-Control Study.
Jobski K; Kollhorst B; Garbe E; Schink T
Drug Saf; 2017 Jun; 40(6):505-515. PubMed ID: 28194654
[TBL] [Abstract][Full Text] [Related]
2. The Risk of Opioid Intoxications or Related Events and the Effect of Alcohol-Related Disorders: A Retrospective Cohort Study in German Patients Treated with High-Potency Opioid Analgesics.
Jobski K; Kollhorst B; Schink T; Garbe E
Drug Saf; 2015 Sep; 38(9):811-22. PubMed ID: 26119289
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain.
Coluzzi F; Ruggeri M
Curr Med Res Opin; 2014 Jun; 30(6):1139-51. PubMed ID: 24528146
[TBL] [Abstract][Full Text] [Related]
4. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice.
Schutter U; Grunert S; Meyer C; Schmidt T; Nolte T
Curr Med Res Opin; 2010 Jun; 26(6):1377-87. PubMed ID: 20380506
[TBL] [Abstract][Full Text] [Related]
5. Switching to low-dose oral prolonged-release oxycodone/naloxone from WHO-Step I drugs in elderly patients with chronic pain at high risk of early opioid discontinuation.
Lazzari M; Marcassa C; Natoli S; Carpenedo R; Caldarulo C; Silvi MB; Dauri M
Clin Interv Aging; 2016; 11():641-9. PubMed ID: 27257377
[TBL] [Abstract][Full Text] [Related]
6. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain.
Vondrackova D; Leyendecker P; Meissner W; Hopp M; Szombati I; Hermanns K; Ruckes C; Weber S; Grothe B; Fleischer W; Reimer K
J Pain; 2008 Dec; 9(12):1144-54. PubMed ID: 18708300
[TBL] [Abstract][Full Text] [Related]
7. Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone.
Morlion B; Clemens KE; Dunlop W
Clin Drug Investig; 2015 Jan; 35(1):1-11. PubMed ID: 25479959
[TBL] [Abstract][Full Text] [Related]
8. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study.
Hermanns K; Junker U; Nolte T
Expert Opin Pharmacother; 2012 Feb; 13(3):299-311. PubMed ID: 22224497
[TBL] [Abstract][Full Text] [Related]
9. Oxycodone/naloxone preparation can cause acute withdrawal symptoms when misused parenterally or taken orally.
Wong A; Macleod D; Robinson J; Koutsogiannis Z; Graudins A; Greene SL
Clin Toxicol (Phila); 2015; 53(8):815-8. PubMed ID: 26109423
[TBL] [Abstract][Full Text] [Related]
10. Developments in managing severe chronic pain: role of oxycodone-naloxone extended release.
Fanelli G; Fanelli A
Drug Des Devel Ther; 2015; 9():3811-6. PubMed ID: 26229442
[TBL] [Abstract][Full Text] [Related]
11. Increases in controlled-release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian population-based study.
Schaffer AL; Karanges EA; Buckley NA; Wilson A; Degenhardt L; Larance B; Pearson SA
Pharmacoepidemiol Drug Saf; 2019 Jan; 28(1):97-105. PubMed ID: 30421838
[TBL] [Abstract][Full Text] [Related]
12. Patient preference with respect to QoL and reduction in opioid-induced constipation (OIC) after treatment with prolonged-release (PR) oxycodone/naloxone compared with previous analgesic therapy [PREFER study].
van Dongen VC; Vanelderen PJ; Koopmans-Klein G; van Megen YJ; Van Zundert J; Huygen FJ
Int J Clin Pract; 2014 Nov; 68(11):1364-75. PubMed ID: 24853258
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
Hale M; Tudor IC; Khanna S; Thipphawong J
Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
[TBL] [Abstract][Full Text] [Related]
14. Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer.
Clemens KE; Quednau I; Klaschik E
Int J Clin Pract; 2011 Apr; 65(4):472-8. PubMed ID: 21401835
[TBL] [Abstract][Full Text] [Related]
15. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.
Trenkwalder C; Beneš H; Grote L; García-Borreguero D; Högl B; Hopp M; Bosse B; Oksche A; Reimer K; Winkelmann J; Allen RP; Kohnen R;
Lancet Neurol; 2013 Dec; 12(12):1141-50. PubMed ID: 24140442
[TBL] [Abstract][Full Text] [Related]
16. Prolonged-release oxycodone/naloxone in postoperative pain management: from a randomized clinical trial to usual clinical practice.
Kuusniemi K; Zöllner J; Sjövall S; Huhtala J; Karjalainen P; Kokki M; Lemken J; Oppermann J; Kokki H
J Int Med Res; 2012; 40(5):1775-93. PubMed ID: 23206459
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis.
Lazzari M; Greco MT; Marcassa C; Finocchi S; Caldarulo C; Corli O
Drug Des Devel Ther; 2015; 9():5863-72. PubMed ID: 26586937
[TBL] [Abstract][Full Text] [Related]
18. Opioid withdrawal syndrome after treatment with low-dose extended-release oxycodone and naloxone in a gastric cancer patient with portal vein thrombosis.
Kang JH; Lee GW; Shin SH; Bruera E
J Pain Symptom Manage; 2013 Aug; 46(2):e15-7. PubMed ID: 23680581
[No Abstract] [Full Text] [Related]
19. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain.
Arora S; Setnik B; Michael D; Hudson JD; Clemmer R; Meisner P; Pixton GC; Goli V; Sommerville KW
J Opioid Manag; 2014; 10(6):423-36. PubMed ID: 25531960
[TBL] [Abstract][Full Text] [Related]
20. Effect of prolonged-released oxycodone/naloxone in postoperative pain management after total knee replacement: a nonrandomized prospective trial.
Oppermann J; Bredow J; Spies CK; Lemken J; Unglaub F; Boese CK; Dargel J; Eysel P; Zöllner J
J Clin Anesth; 2016 Sep; 33():491-7. PubMed ID: 27555214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]